Laurenz De Cock
Overview
Explore the profile of Laurenz De Cock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
40
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verlee M, Dhaenens E, De Cock L, Mosquera L, De Groote K, Vandekerckhove K, et al.
Eur J Hum Genet
. 2025 Jan;
PMID: 39870876
The etiology of congenital heart disease (CHD) is complex, comprising both genetic and environmental factors. Despite documented familial occurrences, the genetic etiology remains largely elusive. Trio exome sequencing identified a...
2.
Billiet L, Jansen H, Pille M, Boehme L, Sanchez Sanchez G, De Cock L, et al.
Eur J Immunol
. 2024 Sep;
54(12):e2451265.
PMID: 39246170
In vitro cultures remain crucial for studying the fundamental mechanisms of human T-cell development. Here, we introduce a novel in vitro cultivation system based on ThymoSpheres (TS): dense spheroids consisting...
3.
Maria Del Rocio P, Palomares Bralo M, Vanhooydonck M, Hamerlinck L, Dhaene E, Leimbacher S, et al.
medRxiv
. 2024 Aug;
PMID: 39148819
8q21.11 microdeletions encompassing the gene encoding transcription factor ZFHX4, have previously been associated by us with a syndromic form of intellectual disability, hypotonia, decreased balance and hearing loss. Here, we...
4.
De Munter S, Buhl J, De Cock L, Van Parys A, Daneels W, Pascal E, et al.
Cancer Immunol Res
. 2024 Jun;
12(9):1236-1251.
PMID: 38874582
CD70 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy for the treatment of both solid and liquid malignancies. However, the functionality of CD70-specific CAR T cells is...
5.
Ingels J, De Cock L, Stevens D, Mayer R, Thery F, Sanchez Sanchez G, et al.
Cell Rep Med
. 2024 Apr;
5(5):101516.
PMID: 38626769
Non-small cell lung cancer (NSCLC) is known for high relapse rates despite resection in early stages. Here, we present the results of a phase I clinical trial in which a...
6.
Perez Baca M, Jacobs E, Vantomme L, LeBlanc P, Bogaert E, Dheedene A, et al.
Am J Hum Genet
. 2024 Feb;
111(3):509-528.
PMID: 38412861
Neurodevelopmental disorders (NDDs) result from impaired development and functioning of the brain. Here, we identify loss-of-function (LoF) variation in ZFHX3 as a cause for syndromic intellectual disability (ID). ZFHX3 is...
7.
Pille M, Avila J, Sanchez Sanchez G, Goetgeluk G, De Munter S, Jansen H, et al.
Front Immunol
. 2023 Jun;
14:1188099.
PMID: 37350958
The Wiskott-Aldrich syndrome (WAS) is an X-linked primary immune deficiency caused by a mutation in the WAS gene. This leads to altered or absent WAS protein (WASp) expression and function...
8.
Perez Baca M, Jacobs E, Vantomme L, LeBlanc P, Bogaert E, Dheedene A, et al.
medRxiv
. 2023 Jun;
PMID: 37292950
Neurodevelopmental disorders (NDDs) result from impaired development and functioning of the brain. Here, we identify loss-of-function variation in as a novel cause for syndromic intellectual disability (ID). ZFHX3, previously known...
9.
Billiet L, De Cock L, Sanchez Sanchez G, Mayer R, Goetgeluk G, De Munter S, et al.
J Exp Med
. 2023 Mar;
220(6).
PMID: 36939517
In the human thymus, a CD10+ PD-1+ TCRαβ+ differentiation pathway diverges from the conventional single positive T cell lineages at the early double-positive stage. Here, we identify the progeny of...
10.
Ingels J, De Cock L, Mayer R, Devreker P, Weening K, Heyns K, et al.
Cytotherapy
. 2021 Oct;
24(2):213-222.
PMID: 34696961
Messenger RNA (mRNA) has become a promising tool in therapeutic cancer vaccine strategies. Owing to its flexible design and rapid production, mRNA is an attractive antigen delivery format for cancer...